This application relates to combination compositions for use in treatment of depression, comprising an effective amount of an N-methyl-D-aspartate receptor (NMDAR) antagonist combined with an anti-depressant agent or an atypical antipsychotic approved for treatment of depression. In a preferred embodiment, D-cycloserine is administered at a dose of about 10 mg/kg/d and is formulated to produce sustained blood levels in excess of about 25 microgram/mL.

Provided herein are methods of using temocillin to control microbial dysbiosis arising from, in certain instances, enterobacteriacea overgrowth such as overgrowth from adherent invasive E. coli (AIEC). Methods of using temocillin to treat intestinal disorders and symptoms of such caused by microbial dysbiosis, as well as other disorders are contemplated herein.

Provided herein are methods of using temocillin to control microbial dysbiosis arising from, in certain instances, enterobacteriacea overgrowth such as overgrowth from adherent invasive E. coli (AIEC). Methods of using temocillin to treat intestinal disorders and symptoms of such caused by microbial dysbiosis, as well as other disorders are contemplated herein.

The present disclosure describes compounds of the general Formula (I) or its stereoisomers, pharmaceutically acceptable salts, poly morphs, sols ales, hydrates, thereof. These compounds or small molecular adjuvants in combination with antibiotics are effective against resistant bacterial infections. The present disclosure also discloses a process of preparation of small-molecular adjuvants, its stereoisomers, pharmaceutically acceptable salts, polymorphs, solvates and hydrates thereof, and to pharmaceutical compositions containing them

##STR00001##

The present disclosure describes compounds of the general Formula (I) or its stereoisomers, pharmaceutically acceptable salts, poly morphs, sols ales, hydrates, thereof. These compounds or small molecular adjuvants in combination with antibiotics are effective against resistant bacterial infections. The present disclosure also discloses a process of preparation of small-molecular adjuvants, its stereoisomers, pharmaceutically acceptable salts, polymorphs, solvates and hydrates thereof, and to pharmaceutical compositions containing them

##STR00001##

The present invention relates to monobactam compounds of Formula I:

##STR00001##

and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of structural formula I or a pharmaceutically acceptable salt therof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of structural formula I, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

The present invention relates to monobactam compounds of Formula I:

##STR00001##

and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of structural formula I or a pharmaceutically acceptable salt therof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of structural formula I, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Compounds and methods for use to treat a bacterial infection caused by, for example, gram positive bacteria, gram negative bacteria, and/or mycobacteria are provided herein. Also provided herein are compounds and methods for use in potentiating the effect of an antibiotic in the treatment of a bacterial infection. Pharmaceutical compositions including the compounds as described herein are also provided.

Compounds and methods for use to treat a bacterial infection caused by, for example, gram positive bacteria, gram negative bacteria, and/or mycobacteria are provided herein. Also provided herein are compounds and methods for use in potentiating the effect of an antibiotic in the treatment of a bacterial infection. Pharmaceutical compositions including the compounds as described herein are also provided.

The present disclosure relates to a method of treating one or more inflammation conditions induced by a coronavirus infection in a subject in need thereof, comprising administering a pharmaceutical composition comprising a compound of Formula I or Formula II, wherein R.sup.1 is halogen, OH, or —OC(O)C1-5alkyl, R.sup.2 and R.sup.3 are each independently selected from CO2R.sup.4 and CH2OR.sup.5; R.sup.4 is Li, Na, K, H, C1-5-alkyl, or —CH2CO(C1-5alkyl); and R.sup.5 is H or —C(O)(C1-5alkyl), or a pharmaceutically acceptable salt thereof.

##STR00001##